Aspiration, Intensive Critical Unit, Pneumonia, Prevention and Control
Conditions
Brief summary
Purpose of the trial: Trial design: Two-parallel arm, double-blind, individually randomized controlled trial. Primary endpoint: Clinical evaluation of sinus, oropharyngeal, tracheal, bronchial or pulmonary infections during orotracheal intubation and hospital admission. Secondary endpoints: Volume of oropharyngeal secretions aspirated per unit of time (for 24 hours) by the SupraTube and Complications during the use of the SupraTube device: erosions, lacerations, Bleeding, displacement, migration, need for withdrawal. Inclusion criteria: * Adult patient * Orotracheal intubation ≤ 72 hours * Hospitalized in ICU * integrity of upper airways Exclusion criteria: * International patients * Coagulopathic patients * oncology patients * patients with maxillofacial surgery * Absence of close responsible family member * Tracheostomy, shock, local or systemic non-controlled infection Trial treatment: Intervention: Aspiration of secretions with the supranav device Control: Usual respiratory care Expected sample size, enrollment and expected number of centers: Sample size = 108 Recruitment start date: Recruitment end date: Follow-up end date: Number of centers: 2 Statistical considerations: * Intention to treat analysis * The primary outcomes will be analyzed using
Interventions
DEVICESupranav
Continuous supraglottic suction device for patients with orotraqueal intubation an mechanical ventilation
Sponsors
Fundación Cardiovascular de Colombia
Study design
Allocation
RANDOMIZED
Intervention model
PARALLEL
Primary purpose
OTHER
Masking
TRIPLE (Caregiver, Investigator, Outcomes Assessor)
Eligibility
Sex/Gender
ALL
Age
18 Years to No maximum
Healthy volunteers
No
Inclusion criteria
* Intubated adult patients with mechanical ventilation. * To have a closest responsible relative * Integrity of the airways
Exclusion criteria
* Need of orofacial, cervical or respiratory tract surgical procedures * Patients with tracheostomy * Shock, * Local or systemic uncontrolled infection * Blood dyscrasia, neoplastic diseases * Physiological alteration * Acute or chronic decompensated pathology that is not controlled at the time of selection.
Design outcomes
Primary
| Measure | Time frame | Description |
|---|---|---|
| Ventilator associated events | 24 hours after extubation | A group of all the conditions that result in a significant and sustained deterioration in oxygenation, defined as a greater than 20% increase in the daily minimum fraction of inspired oxygen or an increase of at least 3 cm H2O in the daily minimum positive end-expiratory pressure (PEEP) to maintain oxygenation. It is imperative to understand that both infectious conditions (such as tracheitis, tracheobronchitis, and pneumonia) and noninfectious conditions (such as atelectasis, pulmonary embolism, pulmonary edema, ventilator-induced lung injury, and others) may fulfill this VAE definition. |
Secondary
| Measure | Time frame | Description |
|---|---|---|
| Adverse events | 24 hours after extubation | Number of patientes with Bleeding and lacerations in the oropharynx |
Countries
Colombia
Outcome results
None listed